ClinicalTrials.gg
Active, not recruitingNCT05548634TAVO412Updated Oct 23, 2024

A Study of TAVO412 in Patients with Cancer

A Phase 1 interventional study of TAVO412 in Cancer, sponsored by Tavotek Biotherapeutics. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-23.

Sponsored by Tavotek Biotherapeutics · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

TAVO412 Phase 1 is an open-label, non-randomized, 2-part Phase I study to examine the safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of TAVO412. Part 1 will utilize a standard 3 + 3 design to determine the MTD/RP2D of TAVO412 in subjects with advanced or metastatic solid tumors who progressed on prior approved standard of care therapy. Part 2 will further evaluate the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), and pharmacologic activity of TAVO412 in a new set of subjects with advanced or metastatic gastric cancer, non-small cell lung cancer (NSCLC), or subjects of other solid tumor types with best clinical responses (e.g., CR > PR > SD) from Part 1 that progressed on prior approved standard of care therapy.

Read the detailed description

This is an open-label, non-randomized, Phase I study to determine the safety and tolerability, define the MTD/RP2D, and assess the preliminary efficacy of TAVO412 in subjects with advanced or metastatic solid tumors who progressed on prior approved standard of care therapy. Subjects will receive TAVO412 at the tested dose intravenously on Day 1 and 15 in Cycle 1 and will continue this bi-weekly treatment schedule for all future cycles.

The study will be conducted in 2 parts:

  • Part 1 - Dose Escalation will determine the MTD and/or RP2D of TAVO412, which includes defining the optimal dose administration schedule.
  • Part 2 - Cohort Expansion will evaluate the recommended dose and administration schedule (MTD/RP2D) determined in Part 1 in a new set of subjects with advanced or metastatic gastric cancer, non-small cell lung cancer (NSCLC), or subjects of other solid tumor types with best clinical responses (e.g., CR > PR > SD) from Part 1 that progressed on prior approved standard of care therapy.
02

Conditions studied

  • Cancer

Browse trials for

03

In context

Neoplasms

10,834 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.

This study's planned enrollment of 50 is below the median of 60 across 7,714 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Tavotek Biotherapeutics is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male/Female aged 18 (at the time of screening) or older.
  2. Willingness to provide written for the study.
  3. Locally disease; locally advanced disease must not be amenable to resection with curative intent.
  4. Subjects who have disease progression after treatment with available therapies that are known to confer clinical benefit, or who are intolerant to treatment, or who refuse standard treatment. There is no limit to the number of prior treatment regimens.
  5. Presence of based on v1.1. Tumor lesions situated in a previously irradiated area, or in an area subjected to other locoregional therapy, are not considered measurable unless there has been demonstrated progression in the lesion.
  6. Part 1: Subjects with advanced or solid tumors who progressed, or refused, or are considered not eligible, on prior approved standard of care therapy. The following will also apply for Part 2 of the study.

    1. Patients with NSCLC who have sensitizing EGFR mutations must have experienced disease progression on prior EGFR TKIs while those with tumor cMET genomic alterations or over-expression must have received prior anti-PD1 agents and platinum-based chemotherapy either in combination or sequentially.
    2. Patients with gastric cancer or gastroesophageal cancer must have received prior cytotoxic chemotherapy and therapy, and where indicated, also received prior -drected therapy or other FDA-approved targeted therapy.
    3. Patients with colorectal cancer must have received fluoropyrimidine, oxaliplatin, and irinotecan ± VEGF-targeting monoclonal antibodies as prior therapy. Patients with RAS-wild type tumors should have received approved anti-EGFR monoclonal antibody. Patients with MSI-high/dMMR colorectal cancer must have received prior immune checkpoint inhibitor therapy
    4. Patients with TNBC must have experienced disease progression on the following as prior therapies:
    5. Pembrolizumab plus chemotherapy (CPS ≥ 10%)
    6. Sacituzumab
    7. Trastuzumab-deruxtecan (HER2-low)
  7. Part 2: A new set of subjects with advanced or metastatic gastric cancer, non-small cell lung cancer (NSCLC), or subjects of other solid tumor types with best clinical responses (e.g., CR > PR > SD) from Part 1 that progressed on prior approved standard of care therapy.

    1. For subjects with Gastric Cancer: confirmed Gastric or Gastro-Esophageal Junction Carcinoma (including adenocarcinoma arising from the lower esophagus). If multiple eligible patients exist, preference will be given to enroll subjects with cMet or EGFR mutations, over-expression, or gene amplification.
    2. For subjects with NSCLC: histologically or cytologically confirmed tumor must be NSCLC with EGFR and/or cMet mutations, over-expression, or gene amplification.
  8. Part 2: Willingness to undergo pretreatment and on-treatment tumor (core or excisional).

    Note: A baseline biopsy obtained for other purposes (i.e., not a protocol-defined procedure) before signing consent may be utilized if the subject has not had any intervening systemic therapy from the time of the biopsy to the start of treatment (i.e., Cycle 1 Day 1), and if a minimum of 20 slides or preferably 1 tissue block can be submitted.

    Note: If a subject is scheduled to have a tumor biopsy for the purposes of this study and it is subsequently determined that tumor tissue cannot safely be obtained, then the subject may still enroll in the study. The subject may be replaced within the cohort.

  9. For both Part 1 \& Part 2, subjects willing to consent to collection of additional blood or tissue samples for exploratory biomarker or genomic analysis purposes.
  10. performance status 0 or 1.
  11. Female subjects of (defined as women who have not undergone surgical sterilization with a hysterectomy and/or bilateral oophorectomy and are not , defined as ≥ 12 months of amenorrhea) must have a negative serum pregnancy test at screening.

    1. All female subjects of child-bearing potential must agree to take appropriate precautions to avoid pregnancy (with at least 99% certainty) from screening through 60 days after the last dose of study drug.
    2. All male subjects must agree to take appropriate precautions to avoid pregnancy with a partner (with at least 99% certainty) from screening through 90 days after the last dose of study drug. Permitted methods that are at least 99% effective in preventing pregnancy (see Appendix A) should be communicated to the subjects and their understanding confirmed.
  12. Patients with prior of the same or different tumor type and patients with concurrent malignancies of the same or different tumor type will be included
  13. Patients with mild and moderate hepatic impairment (defined as the equivalent of National Cancer Institute (NCI CTCAE) grade 1 toxicity), as well as those with (AST) and alanine transaminase (ALT) elevations defined as grade 3 by the NCI CTCAE (> 5 to 20 x (upper limit of normal)), may be asymptomatic and able to tolerate doses equivalent to patients with normal hepatic function
  14. Patients with compromised renal function must meet ≥ 30 mL/minute (estimated by the Cockcroft-Gault formula, [140 - age] × body weight/plasma creatinine × 72 [× 0.85 if female])
  15. Patients with (HIV)/ (HBV)/ (HBC) will be allowed to enter into the study provided the following criteria are met:

    a) Patients with HIV infection must have CD4+ T-cell (CD4+) counts ≥ 350 cells/µL.

  16. The following eligibility criteria are for patients with evidence of chronic HBV infection or patients with history of chronic hepatitis C virus (HCV) or who are virologically suppressed on HCV treatment:

    1. Liver-related laboratory eligibility criteria should be the same as that for the general population.
    2. Exceptions: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) and criteria may be less stringent in patients with cancers such as hepatocellular carcinoma and cholangiocarcinoma in whom hepatic function based on score should be used.
    3. Patients with chronic HBV infection with active disease who meet the criteria for anti-HBV therapy should be on a suppressive antiviral therapy prior to initiation of cancer therapy.

      Note: Subjects with no prior history of hepatitis B infection who have been vaccinated against hepatitis B and who have a positive antibody against hepatitis B surface antigen test as the only evidence of prior exposure may participate in the study.

    4. Patients on concurrent HCV treatments must have HCV below the limit of quantification.
    5. Patients with untreated HCV may be enrolled if the HCV is stable, the patient is not at risk for hepatic decompensation, and the cancer treatment is not expected to exacerbate the HCV infection.
  17. Patients without a history of AIDS-defining opportunistic infections or no opportunistic infection within the past 12 months. With the exception of:

    1. Patients with a history of AIDS-defining cancers (e.g., Kaposi's sarcoma, aggressive B-cell lymphoma, and invasive cervical cancer).
    2. Patients on prophylactic antimicrobials where there may be drug-drug interactions or overlapping toxicities should if appropriate, be changed to an alternative antimicrobial, or if not, be excluded.
  18. To ensure that effective antiretroviral therapy is tolerated and that toxicities are not confused with investigational drug toxicities, trial participants should be on established ART for at least four weeks and have an HIV viral load less than 400 copies/mL prior to enrollment. However, exclusion may be based on specific ART drugs with overlapping toxicity.

Exclusion criteria

Exclusion Criteria:

  1. Laboratory and medical history parameters not within the protocol-defined range. If the screening laboratory tests below were conducted > 7 days before treatment initiation, they will need to be repeated on Day 1 before initiation of treatment.

    1. \< 1.5 × 109/L.
    2. \< 100 × 109/L.
    3. \< 9 g/dL or \< 5.6 mmol/L.
    4. \< 30 mL/minute (estimated by the Cockcroft-Gault formula, [140 - age] × body weight/plasma creatinine × 72 (× 0.85 if female)
    5. , alanine aminotransferase, and alkaline phosphatase ≥ 2.5 × .

      Note: Subjects with 1) bone and 2) no hepatic parenchymal metastases on screening radiographic examinations may enroll if the alkaline phosphatase ≤ 5 × ULN. Subjects with 1) bone metastases and/or 2) hepatic parenchymal metastases on screening radiographic examinations may enroll if the alkaline phosphatase is ≤ 5 × ULN only with medical monitor approval.

    6. Total ≥ 1.5 × ULN unless conjugated bilirubin ≤ ULN (note: conjugated bilirubin only needs to be tested if total bilirubin exceeds ULN). If there is no institutional ULN, then direct bilirubin must be \< 40% of total bilirubin.
    7. , prothrombin time, or activated partial thromboplastin time > 1.5 × ULN.
  2. Transfusion of blood products (including platelets or red blood cells) or administration of colony stimulating factors (including granulocyte colony-stimulating factor, granulocyte macrophage colony- stimulating factor, or recombinant erythropoietin) within 14 days before study Day 1.
  3. Receipt of anti-cancer medications or drugs within the following intervals before the first administration of study drug:

    1. ≤ 14 days for chemotherapy, targeted small molecule therapy, or radiation therapy. Subjects must also not require chronic use of and must not have had radiation pneumonitis as a result of treatment. A 1-week is permitted for palliative radiation to non-central nervous system (CNS) disease with sponsor approval.

      Note: Bisphosphonates and denosumab are permitted concomitant medications.

    2. ≤ 28 days for prior immunotherapy or persistence of active cellular therapy (i.e., chimeric antigen receptor T-cell therapy; other cellular therapies must be discussed with medical monitor to determine eligibility).
    3. ≤ 28 days for a prior monoclonal antibody used for anticancer therapy with the exception of denosumab.
    4. ≤ 7 days for immune-suppressive-based treatment for any reason. Note: Use of inhaled or topical steroids or corticosteroid use for radiographic procedures is permitted.

      Note: The use of physiologic corticosteroid replacement therapy may be approved after consultation with the medical monitor.

    5. ≤ 28 days or 5 half-lives (whichever is longer) before the first dose for all other investigational agents or devices. For investigational agents with long half-lives (e.g., > 5 days), enrollment before the fifth half-life requires medical monitor approval.
  4. Has not recovered to ≤ Grade 1 from toxic effects of prior therapy (including prior immunotherapy) and/or complications from prior surgical intervention before starting therapy.

    Note: Subjects with stable chronic AEs (≤ Grade 2) not expected to resolve (such as neuropathy and alopecia) are exceptions and may enroll with medical monitor approval.

    Note: Subjects with a history of any grade immune-related ocular AEs will be excluded.

    Note: Subjects with a history of a Grade 3 or higher immune-related AE from prior immunotherapies are excluded from the dose escalation portion of the study.

  5. Receipt of a within 30 days of planned start of study drug. Note: Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox/zoster, yellow fever, rabies, Bacillus Calmette-Guérin, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; COVID booster vaccines are permitted ≥ 4 weeks post; however, intranasal influenza vaccines are live attenuated vaccines and are not allowed.
  6. Active disease that required systemic treatment in the past (i.e., with use of disease-modifying agents, corticosteroids, or drugs).

    Note: Subjects who have not required systemic treatment in the past 2 years should discuss their case with medical monitor to determine eligibility.

    Note: Subjects with hyper/hypothyroidism are eligible to participate. Note: Replacement and symptomatic therapies (e.g., levothyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) are not considered a form of systemic treatment and are allowed.

  7. Known active and/or carcinomatous meningitis. Note: Subjects with previously treated brain metastases may participate provided that they are stable (without evidence of progression by imaging for at least 28 days before the first dose of study drug and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases or CNS edema, and have not required steroids for at least 14 days before the first dose of study drug.
  8. Evidence of active, noninfectious pneumonitis or history of interstitial lung disease.
  9. Active infection requiring systemic therapy, including COVID-19.
  10. Known allergy or reaction to any component of study drug or formulation components.
  11. Is a female who is pregnant or breast feeding, or expecting to conceive children within the projected duration of the study, starting with the screening visit through 60 days after the last dose of study drug OR;
  12. Is a male who is expected to father children within the duration of the study, starting with the screening visit through 90 days after the last dose of study drug.
  13. Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the subject; or interfere with interpretation of study.
  14. Inability to comprehend or unwillingness to sign the form (ICF).
  15. Subject has a history of class III or IV congestive heart failure or severe nonischemic cardiomyopathy, unstable or poorly controlled angina, myocardial infarction, ventricular arrhythmia, or coronary/peripheral artery bypass graft within the previous 6 months of starting study treatment. Furthermore, subject should have no history of cerebrovascular accident, , or symptomatic pulmonary embolism, or uncontrolled hypertension.
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Other
    Part 1 Cohort 0

    IV infusion of TAVO412

    Drug: TAVO412

  • Other
    Part 1 Cohort 1

    IV infusion of TAVO412

    Drug: TAVO412

  • Other
    Part 1 Cohort 2

    IV infusion of TAVO412

    Drug: TAVO412

  • Other
    Part 1 Cohort 3

    IV infusion of TAVO412

    Drug: TAVO412

  • Other
    Part 1 Cohort 4

    IV infusion of TAVO412

    Drug: TAVO412

  • Other
    Part 1 Cohort 5

    IV infusion of TAVO412

    Drug: TAVO412

  • Other
    Part 2 Cohorts

    IV infusion of TAVO412

    Drug: TAVO412

Interventions

  • DrugTAVO412

    Biologic

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability of TAVO412 according to Adverse Events and Number of Participants With Dose Limiting Toxicity (DLT) using National Cancer Institute CTCAE v5.0

    According to the frequency, duration, and severity of Adverse Events (AEs). The Dose Limiting Toxicity (DLT) is based on drug related adverse events and includes unacceptable hematologic toxicity, non-hematologic toxicity of Grade 3 or higher, or elevations in hepatic enzymes suggestive of drug-induced liver injury. The Common Terminology Criteria for Adverse Events (CTCAE) v5.0 has a minimum value of Grade 1, or mild, and a maximum value of Grade 4, Life-threatening; pressor or ventilatory support indicated. All DLTs will be assessed by the investigator using National Cancer Institute CTCAE v5.0.

    Time frame: Approximately 12 months

Secondary outcomes

  1. Maximum Serum Concentration (Cmax) of TAVO412

    The Cmax is the maximum observed serum concentration of TAVO412.

    Time frame: Approximately 12 months

  2. Time to Reach Maximum Observed Serum Concentration (Tmax) of TAVO412

    The Tmax is defined as time to reach maximum observed serum concentration of TAVO412.

    Time frame: Approximately 12 months

  3. Minimum Serum Concentration (Cmin) of TAVO412

    The Cmin is the minimum observed serum concentration of TAVO412.

    Time frame: Approximately 12 months

  4. Area Under the Serum Concentration-Time Curve From 0-1 (AUC[t0-t1])

    The AUC(t0-t1) is the area under the serum TAVO412 concentration-time curve from time t0 to t1.

    Time frame: Approximately 12 months

  5. Overall Response Rate (ORR)

    ORR is defined as the percentage of subject having complete response (CR) or partial response (PR).

    Time frame: Approximately 12 months

  6. Duration of Response (DOR)

    DOR is defined as the time from earliest date of disease response (CR or PR) until earliest date of disease progression.

    Time frame: Approximately 12 months

  7. Progression-Free Survival (PFS)

    PFS is defined as the time from date of first dose of study drug until the earliest date of disease progression.

    Time frame: Approximately 12 months

  8. Duration of Disease Control (CR, PR, and SD)

    Duration of disease control is defined as the sum of PFS followed by maintenance.

    Time frame: Approximately 12 months

07

Study locations

1 site
  • Tisch Cancer Center
    NYC, New York 10029, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Dec 2025, 31 months after the start.

Of 676 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's planned 31 months is below that.

Counting every sponsor, half of 903 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2022
First posted
Sep 21, 2022
StartActual
May 8, 2023
Primary completionEst.
Dec 30, 2025
CompletionEst.
Jun 1, 2026
Last update
Oct 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05548634
Lead sponsor
Tavotek Biotherapeutics
Responsible party
Sponsor
First posted
Sep 21, 2022
Start date
May 8, 2023
Primary completion
Dec 30, 2025 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
Oct 23, 2024

Study contacts

Deborah Doroshow, MD
principal investigator · MOUNT SINAI HOSPITAL

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion